The novel coronavirus disease-2019 (COVID-19) is an ongoing pandemic and currently, no specific vaccines or modern drugs are available to combat this contagious viral disease. Kaba sura kudineer, an official polyherbal Siddha medicine containing numerous herbal ingredients, is being practiced primarily in southern parts of India in the management of COVID-19 pandemic for boosting the respiratory system and treating fever with flu-like symptoms. The present study is carried out to scientifically validate the traditional claim and to confirm identity, quality and purity of marketed kaba sura kudineer polyherbal formulations in India. Kabasura kudineer chooranam manufactured by two different manufacturers were procured from New Delhi, India. The physicochemical characterization of the samples was carried out in accordance with the standards laid down by Indian Pharmacopoeia (IP) 2018. HPTLC profiling of key ingredients including Kalmegh (Andrographis paniculata), Guduchi (Tinospora cordifolia), Pippali (Piper longum), Vasaka (Adhatoda vasica) and Lavang (Syzygium aromaticum) were also carried out in accordance with IP 2018 monographs. The chromatographic analysis showed presence of all major ingredients in both the marketed preparations and all the physicochemical properties were also found comparable among preparations. Our findings may enhance the global acceptance of Siddha medicines practiced widely in India and also used for laying down the pharmacopoeial standards of kaba sura kudineer chooranam